BFC Planning’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.06K Sell
22
-4
-15% -$870 ﹤0.01% 2767
2026
Q2
$6.36K Sell
26
-1
-4% -$217 ﹤0.01% 2580
2026
Q1
$4.56K Sell
27
-11
-29% -$1.9K ﹤0.01% 2342
2025
Q4
$6.94K Hold
38
– – ﹤0.01% 2217
2025
Q3
$4.62K Buy
38
+4
+12% +$451 ﹤0.01% 2224
2025
Q2
$3.55K Sell
34
-5
-13% -$529 ﹤0.01% 2169
2025
Q1
$4.55K Buy
39
+14
+56% +$1.6K ﹤0.01% 2051
2024
Q4
$2.12K Sell
25
-6
-19% -$552 ﹤0.01% 2273
2024
Q3
$2.79K Buy
+31
New +$2.71K ﹤0.01% 2198

Other funds holding AXSM

BFC Planning's AXSM Position: Q3 2026 in Review

BFC Planning reduced its Axsome Therapeutics (AXSM) stake by 15% in Q3 2026, selling an estimated $870 and leaving 22 shares worth $4.06K. The position accounts for ﹤0.01% of the portfolio, ranked #2767.

BFC Planning first reported a position in AXSM in Q3 2024 and has held it in 9 quarters since. The position peaked at $6.94K in Q4 2025. 349 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • BFC Planning held 22 shares of Axsome Therapeutics worth $4.06K as of Q3 2026.
  • BFC Planning sold 4 Axsome Therapeutics shares in Q3 2026, an estimated $870.
  • Axsome Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #2767 holding.
  • BFC Planning first reported a position in Axsome Therapeutics in Q3 2024 and has held it in 9 quarters since.
  • BFC Planning's Axsome Therapeutics position peaked at $6.94K in Q4 2025.
  • 349 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.